🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Frances Priddy

Moderna Therapeutics (United States)

ORCID: 0000-0002-2533-3982
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial”.

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Nature Medicine(2021)10.1038/s41591-021-01509-0
N/A
2.3DataRank · unranked
104 citations

Boris Jülg, Chen Sabrina Tan, Rebecca Zash, Stephen R. Walsh, Charlotte-Paige Rolle +35 more

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial

Nature Communications(2025)10.1038/s41467-025-61153-x
N/A
0.477DataRank · unranked
23 citations

Jiejun Du, Lan Lan, Archana Kapoor, Gonzalo Perez Marc, Gilberto Jimenez +13 more

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae689
N/A
0.444DataRank · unranked
8 citations

Xiaowei Wang, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Peter B. Gilbert +13 more

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Nature Communications(2024)10.1038/s41467-024-52348-9
N/A
0.428DataRank · unranked
9 citations

Youyi Fong, Jonathan Fintzi, Eric Chun‐Pu Chu, Holly Janes, Avi Kenny +37 more

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad500.2470
N/A
0.208DataRank · unranked
3 citations

Xiaowei Wang, Peter B. Gilbert, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink +10 more

Long-term safety and efficacy of COVE study open-label and booster phases

Research Square(2024)10.21203/rs.3.rs-3900939/v1
N/A
0DataRank · unranked
0 citations

Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout +19 more

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

UNC Libraries(2024)10.17615/18qe-2h49
N/A
0DataRank · unranked
0 citations

Fichtenbaum C.J, Youyi Fong, Isabel Reeder, Gilbert P.B., Spyros A. Kalams +34 more

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf572
N/A
0DataRank · unranked
0 citations

Lauren Dang, Eric Chun‐Pu Chu, Jonathan Fintzi, Holly Janes, Peter B. Gilbert +13 more